AIM- Systemic Sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, immune activation and fibrosis of the skin and internal organs. Interstitial lung disease (ILD) is one of the most common causes of death. In 2019 Nintedanib was approved for SSc-related ILD, due to randomized clinical trials (RCTs) demonstrating a reduction in the annual rate of decline in Forced Vital Capacity (FVC). METHODS We reviewed eleven patients with SSc-related ILD from January 2020 to January 2021 and who started Nintedanib 150 mg twice a day. RESULTS- Non-Specific Interstitial Pneumonia (NSIP) was the most frequent HRCT pattern, followed by Usual Interstitial Pneumonia (UIP) and UIP/NSIP pattern. The mean of Modified Rodnan Skin Score (mRSS) at baseline was 9.23 (±10SD) points without any significant improvement during the follow-up. Patients continued their ongoing therapy for lung involvement. Mean FVC was 2233.6 ml [+/- 1066 ml] (61.3% predicted) at beginning and remained stable during the follow-up period. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 at baseline to 2.5 at the end of follow up and the mean of the Borg scale of dyspnea ameliorated from 7.27 at baseline to 6 at twelve months. Both the differences were not significant. Two patients stop therapy: one for partial intestinal obstruction and one for incoercible diarrhea. CONCLUSION- Nintedanib was generally well tolerated and we did not record any serious adverse event

One-year clinical experience on the use of Nintedanib in Systemic Sclerosis / Magnani, Luca; Spinella, Amelia; Testoni, Sofia; Lumetti, Federica; Scelfo, Chiara; Dardani, Lucia; Bajocchi, Gianluigi; Clini, Enrico; Salvarani, Carlo; Giuggioli, Dilia. - In: RESPIROLOGY CASE REPORTS. - ISSN 2051-3380. - 11:6(2023), pp. 1-4. [10.1002/rcr2.1120]

One-year clinical experience on the use of Nintedanib in Systemic Sclerosis

Luca Magnani;Amelia Spinella;Sofia Testoni;Federica Lumetti;Enrico Clini;Carlo Salvarani;Dilia Giuggioli.
2023

Abstract

AIM- Systemic Sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, immune activation and fibrosis of the skin and internal organs. Interstitial lung disease (ILD) is one of the most common causes of death. In 2019 Nintedanib was approved for SSc-related ILD, due to randomized clinical trials (RCTs) demonstrating a reduction in the annual rate of decline in Forced Vital Capacity (FVC). METHODS We reviewed eleven patients with SSc-related ILD from January 2020 to January 2021 and who started Nintedanib 150 mg twice a day. RESULTS- Non-Specific Interstitial Pneumonia (NSIP) was the most frequent HRCT pattern, followed by Usual Interstitial Pneumonia (UIP) and UIP/NSIP pattern. The mean of Modified Rodnan Skin Score (mRSS) at baseline was 9.23 (±10SD) points without any significant improvement during the follow-up. Patients continued their ongoing therapy for lung involvement. Mean FVC was 2233.6 ml [+/- 1066 ml] (61.3% predicted) at beginning and remained stable during the follow-up period. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 at baseline to 2.5 at the end of follow up and the mean of the Borg scale of dyspnea ameliorated from 7.27 at baseline to 6 at twelve months. Both the differences were not significant. Two patients stop therapy: one for partial intestinal obstruction and one for incoercible diarrhea. CONCLUSION- Nintedanib was generally well tolerated and we did not record any serious adverse event
2023
23-mag-2023
11
6
1
4
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis / Magnani, Luca; Spinella, Amelia; Testoni, Sofia; Lumetti, Federica; Scelfo, Chiara; Dardani, Lucia; Bajocchi, Gianluigi; Clini, Enrico; Salvarani, Carlo; Giuggioli, Dilia. - In: RESPIROLOGY CASE REPORTS. - ISSN 2051-3380. - 11:6(2023), pp. 1-4. [10.1002/rcr2.1120]
Magnani, Luca; Spinella, Amelia; Testoni, Sofia; Lumetti, Federica; Scelfo, Chiara; Dardani, Lucia; Bajocchi, Gianluigi; Clini, Enrico; Salvarani, Car...espandi
File in questo prodotto:
File Dimensione Formato  
Magnani (Nintedanib in SS-pulmonary fibrosis- 2023).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 259.03 kB
Formato Adobe PDF
259.03 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1305007
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact